Tiny Hearts, Big Insights: Scientists Grow Mini Hearts to Uncover Drug Risks in Pregnancy

Exploring How Drugs Affect Fetal Heart Development 

Researchers are pushing the boundaries of biomedical science by growing miniature human hearts in the lab. These tiny, organ-like structures, known as organoids, are providing crucial insights into how various drugs might affect fetal heart development. This breakthrough could be key in understanding and preventing congenital heart defects, the most common type of birth defect worldwide.

The Intricacies of Heart Development

The human heart is the first organ to fully function during embryonic development, starting to pump blood by the fourth week of gestation. By the ninth week, the heart is fully formed. This early formation exposes the developing heart to various substances the pregnant person might encounter, including medications and environmental pollutants, which can lead to congenital heart diseases (CHD).

CHD affects over 1 in 100 births globally, a staggering statistic that highlights the need for advanced research methods. Traditional studies using animal models and cell cultures have not been able to fully replicate the complexity of the human heart, thus limiting the understanding of these defects.

Creating Human Heart Organoids

To overcome these limitations, a team of biomedical engineers and cardiovascular scientists have developed heart organoids using pluripotent stem cells. These stem cells can become any cell type in the body and are now derived from adult cells, making their use less controversial.

By guiding pluripotent stem cells to become heart cells, researchers can create organoids that mimic the main stages of heart development during pregnancy. These heart organoids, although smaller than a grain of rice, have blood vessels and the various cell types found in a human heart, such as cardiomyocytes and pacemaker cells. Their electrophysiology and bioenergetics closely resemble those of embryonic hearts, providing a more accurate model for studying heart development and disease.

Investigating Maternal and Fetal Cardiac Health

One significant application of these heart organoids is studying how maternal health conditions impact fetal heart development. Conditions like diabetes, hypertension, and even depression can increase the risk of CHD. For instance, researchers have used heart organoids to demonstrate that diabetes can lead to heart abnormalities in embryos. Organoids exposed to diabetic conditions developed defects similar to those observed in human fetuses with diabetic cardiomyopathy.

The study identified an imbalance of omega-3 fatty acids as a potential cause of these abnormalities. Encouragingly, dietary supplementation of omega-3 fatty acids was found to partially restore this balance and prevent diabetes-induced congenital heart defects.

Evaluating Drug Safety During Pregnancy

The medications taken during pregnancy can have profound effects on both the pregnant person and the fetus. However, ethical concerns limit the ability to test drugs on pregnant people, and animal models do not sufficiently replicate human physiology. This gap in research can lead to medications being approved without a full understanding of their potential risks.

Heart organoids offer a promising solution. For example, ondansetron (Zofran), a drug prescribed to prevent nausea during pregnancy, has been linked to an increased risk of congenital heart disease. Studies using heart organoids showed that exposure to ondansetron disturbed the development of ventricular cells and impaired heart function, mirroring defects seen in newborns exposed to the drug.

Antidepressants, particularly selective serotonin reuptake inhibitors (SSRIs), are another concern. These medications, which alter serotonin levels, are commonly prescribed during pregnancy. Since serotonin is crucial for cardiac development, exposure to SSRIs may increase the risk of CHD. Future research on heart organoids exposed to antidepressants could lead to safer guidelines for their use during pregnancy.

The Future of Heart Organoid Research

Heart organoids hold immense potential for advancing our understanding of how the human heart forms and develops diseases. This research not only promises to improve the safety of medications used during pregnancy but also offers hope for developing new treatments for congenital heart defects. As scientists continue to refine these mini hearts, they move closer to a future where congenital heart diseases can be better understood, prevented, and treated.

_____________________________________________________________________________

Vertical Bar Media

For more information on advanced biomedical research and its applications, explore Vertical Bar Media. Let Vertical Bar Media help you share groundbreaking scientific discoveries with the world.

Source: Live Science

Photo Credit:  Yonatan R. Lewis-Israeli et al. 2021/Nature Communications

Social Media Hashtags: #HeartHealth #StemCellResearch #PregnancySafety #BiomedicalInnovation